

RESEARCH SEMINAR SERIES

Drug Development from the Inside

October 23, 2024 | 12:00 pm – 12:50 pm

050 Apotex Centre, Bannatyne Campus



Dr. Mark S. Williams

Drug Development Entrepreneur
Marvel Biosciences

Speaker Biosketch: Mark is currently the President & CSO of Marvel Biosciences (TSX-V) and held previous senior management positions as CSO of Algernon Pharmaceuticals (CSE, US-OTC) and VP Research for DiaMedica (NASDAQ). While at the latter, he lead all aspects of pre-clinical development through to Phase 2 trials of DM-199, recombinant tissue kallikrein. DM-199 received FDA Fast-track designation for the treatment of ischemic stroke and is in Phase 3 trials.